BeNeLuxBelgiumNetherlandsLuxembourg

Alliances pay off

04.11.2010

Mechelen – Genomics and drug discovery services company Galapagos NV, has triggered another milestone payment in its alliance with Janssen Pharmaceutica NV in the field of rheumatoid arthritis, receiving a milestone payment of EUR1.5m. To date, Galapagos has earned more than EUR24m in payments from Janssen under the alliance. At the same time, the Mechelen-based company said it had received a a 1m milestone payment under its alliance with GlaxoSmithKline in the field of infectious disease. Since the initiation of the GSK deal at the end of 2007, Galapagos has received a total of a 6m from the pharma giant. “Galapagos continues to make progress across its strategic alliances, showing that our alliance ­model delivers strong growth in R&D revenues,” said CEO of Galapagos Onno van de Stolpe.

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Mechelen - Galapagos NV confirms its status as one of Europe best drug discovery companies. The Belgian biotech received €4 million as the first milestone payments from French Servier for the discovery of new targets for...

BeNeLuxBelgiumNetherlandsLuxembourg

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted...

BeNeLuxBelgiumNetherlandsLuxembourg

02.12.2011

Zwijnaarde/Rotterdam – In vivo camelid antibody specialist arGEN-X BVBA has baged €27.5 million of fresh capital for development of its preclinical monoclonal antibody pipeline. The round B financing of the 3 year-old company,...

BeNeLuxBelgiumNetherlandsLuxembourg

28.11.2011

Brussels/Ghent – Belgian researchers have demonstrated that tumour cells secrete the angiogenesis factor VEGF to create a microenvironment that fosters proliferation of cancer stem cells. In mice with squamous cell carcinoma,...

BeNeLuxBelgiumNetherlandsLuxembourg

23.11.2011

Mechelen – Belgian drugmaker Galapagos NV has reported impressive results of a proof-of-concept trial with its oral janus kinase 1 blocker GLPG0634 + Methothrexate in patients with active rheumatoid arthritis. In the 24 patients...

BeNeLuxBelgiumNetherlandsLuxembourg

18.11.2011

Naarden – Enzyme replacement therapies specialist Oxyrane NV raised €20 million in a series D round of financing. The therapies are designed to treat lysosomal storage diseases, a class of more than forty rare inherited diseases....

BeNeLuxBelgiumNetherlandsLuxembourg

14.11.2011

Hilden/Venlo – Sample and assay technologies provider Qiagen N.V. is set to eliminate about 10% of its current global workforce of 3,800 employees. The company says the cuts are one result of implementing a project aimed at...

BeNeLuxBelgiumNetherlandsLuxembourg

09.11.2011

New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage...

BeNeLuxBelgiumNetherlandsLuxembourg

25.10.2011

Amsterdam - The second blow could be the ultimate one. Amsterdam Molecular Therapeutics received a second negative opinion for Glybera to treat lipoprotein lipase (LPL) deficiency. The European Medicines Agency's (EMA) Committee...

BeNeLuxBelgiumNetherlandsLuxembourg

13.10.2011

Bilthoven – The current impact of hospital acquired infections with multi-resistant bugs is lower than suggested by startling news articles. According to a study of Dutch researchers, bloodstream infections caused by...

Displaying results 11 to 20 out of 304

< Previous 11-20 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/1/article/alliances-pay-off.html

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week

Products

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • MEDIGENE10.96 EUR4.88%
  • EVOLVA1.58 CHF3.27%

FLOP

  • BIOTEST71.00 EUR-3.92%
  • SYNGENTA314.40 CHF-3.65%
  • 4SC5.03 EUR-3.27%

TOP

  • 4SC5.03 EUR293.0%
  • WILEX4.33 EUR51.4%
  • SARTORIUS151.00 EUR21.2%

FLOP

  • CYTOS1.01 CHF-29.4%
  • BIOTEST71.00 EUR-26.9%
  • BIOFRONTERA2.30 EUR-11.2%

TOP

  • SANTHERA96.45 CHF2329.5%
  • CYTOS1.01 CHF676.9%
  • WILEX4.33 EUR397.7%

FLOP

  • MOLOGEN4.94 EUR-55.4%
  • BIOFRONTERA2.30 EUR-29.2%
  • BIOTEST71.00 EUR-20.0%

No liability assumed, Date: 03.05.2015

Current issue

All issues